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Background: Renal failure is one of the main causes of death in patients with Fabry disease
(FD).  Due to the low prevalence of FD, delayed diagnosis and misdiagnosis, often the correct
diagnosis is made when organ damage is already present. Early recognition of the disease
would allow the prevention of severe complications and the premature death of patients
with  FD.
Objective: We  present here the PrEFiNE project, which includes a wide spectrum of activities
with  the aim of improve knowledge and diagnosis of FD.
The project is sponsored by Shire Iberia (http://shireiberica.com/).
Methods: From January 2016 to the end of 2017 several activities will be carried out, starting
with  a survey to evaluate current FD knowledge among nephrologists; in addition some stud-
ies  to assess prevalence of this disease will be performed. One study will include patients
receiving dialysis, another study will cover kidney transplant patients, and a pilot study in
chronic kidney disease in stage 3–5 predialysis. Also planned is a pharmacoeconomic study
to  focus on burden of FD. At the same time medical education activities will be conducted
both  on line and on site. Plan for dissemination will include medical publications and dif-
fusion to media. PrEFiNE Project will ﬁnish with the publication of a compilation book on
FD  in Nephrology including all planned activities and proposing recommendations basedon  results and detected unmet needs.
 coordinated by severa scientiﬁc committees, one at national level andPrEﬁNE Plan will be10  other regionals committees, that will be responsible to ensure the maximum scientiﬁc
quality of proposed activities. An advisory board will supervise the project.
 Please cite this article as: del Pino MD, Ortiz A, Torra R, Hernandez D. Plan PrEFiNE: Plan estratégico para la enfermedad de Fabry en
Nefrología. Nefrología. 2016;36:376–380.
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Discussion: PrEﬁNE project will evaluate an action plan focused on improving FD knowledge
to  make necessary recommendations for an early recognition of the disease. In addition will
generate a plan to improve previously undetected needs.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Justiﬁcación: La enfermedad renal es una de las principales causas de muerte entre los
pacientes con enfermedad de Fabry (EF). Al tratarse de una enfermedad de baja prevalencia,
se  realizan con frecuencia diagnósticos erróneos y retrasados, que a menudo se dan cuando
ya  se ha producido dan˜o orgánico. El reconocimiento temprano de la enfermedad permitiría
evitar las complicaciones graves y la muerte prematura en estos pacientes.
Objetivo: Presentamos en este artículo un resumen del plan PrEFiNE, que incluye un abanico
amplio de actividades con el objetivo de mejorar el conocimiento y reconocimiento de la EF
entre los nefrólogos.
Este proyecto está patrocinado por Shire Ibérica (http://shireiberica.com/).
Métodos: Desde enero de 2016 y hasta ﬁnales del 2017 se iniciarán distintas actividades,
comenzando por una evaluación del grado de conocimiento que existe actualmente sobre
la  EF. Se incluyen 3 estudios de prevalencia de la EF, que abarcan el espectro de los pacientes
con  enfermedad renal crónica (pacientes en diálisis, pacientes trasplantados renales y un
estudio piloto en pacientes con enfermedad renal crónica en estadio 3–5 prediálisis) y un
estudio farmacoeconómico, centrado en el impacto de la carga de la enfermedad. Parale-
lamente, se realizarán actividades formativas tanto presenciales como on line,  y un amplio
plan de comunicación mediante publicaciones y difusión a medios. El proyecto culminará
con  la publicación de un libro blanco de la EF en Nefrología, que recoja el resultado de
todas  las actividades y que proponga recomendaciones en respuesta a los resultados y a las
necesidades detectadas.
El plan PrEFiNE estará coordinado por distintos comités cientíﬁcos, uno nacional y 10
regionales que garantizarán el desarrollo de las acciones con el máximo rigor cientíﬁco
y  será supervisado por un comité asesor.
Discusión: El plan PrEFiNE nos permitirá evaluar la utilidad de un proyecto dirigido a mejorar
el  conocimiento de una enfermedad minoritaria como la EF a nivel nacional, y a partir del
cual  se podrán establecer las recomendaciones necesarias para mejorar su reconocimiento,
además de planes enfocados a mejorar las necesidades no cubiertas detectadas durante su
desarrollo.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
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introduction
abry’s disease (FD) is a lysosomal disease that is characterised
y a deﬁciency in -galactosidase A, an enzyme that causes
lycosphingolipids, mainly globotriaosylceramide (Gb3), to be
eposited in the vascular endothelium and other tissues. It is a
rogressive disease that causes manifestations in the kidneys,
eart, nervous system, skin, eyes and other systems.1,2
It is considered to be a rare disease, as it affects 1 in
0,000–238,000 males.2–4 However, studies conducted using
eonatal screening have observed a greater incidence, of
/3100 to 1/4100 live births for late-onset forms and 1/37,000
or classic phenotypes.5,6 Obviously, its frequency is greater
n high-risk populations such as the population affected byby-nc-nd/4.0/).
chronic kidney disease (CKD) that requires dialysis or the
population suffering from by left ventricular hypertrophy or
stroke.7 Life expectancy is normally shortened by 20 years
in men8 and 15 years in women.9 One of the main causes
of death in patients with FD is renal failure and it occurs
very early, in the fourth or ﬁfth decade of life, particularly in
males.10,11
One analysis of patients with FD determined that more
than 25% had been diagnosed incorrectly initially12 and that
their diagnosis took an average of 12 years to conﬁrm.13 Diag-
nosis tends to be delayed by at least 3 years, but it often takes
20 years after the onset of signs and symptoms. Some patients
have even experienced delays of more  than 50 years.12 Patients
with FD and already impaired renal function have a more
unfavourable prognosis than those without it.14
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In clinical practice there is no unanimous agreement for
including FD as part of the differential diagnosis of patients
with CKD in any stage. This makes it difﬁcult to diagnose
the disease early, identify at-risk family relatives and prevent
other secondary and potentially deadly complications of the
disease.
As generally occurs with rare diseases, part of the problem
may lie in limited awareness of the disease such that a diag-
nosis of FD may not be considered as part of the diagnostic
algorithm for patients with CKD.
The PrEFiNE plan was created with the aim of improving
knowledge and recognition of FD among all nephrologists,
which would allow an early diagnosis of the disease and an
early approach to patients who  have it. The aims of this plan
are many  and range from evaluating current knowledge of FD
and establishing its prevalence in patients with CKD (dial-
ysis, transplant and stage 3–5 CKD predialysis); evaluating
the impact of FD from a healthcare-related, sociological and
economic point of view; improving knowledge of FD through
speciﬁc training in the disease; detecting potential unmet
needs in the approach to FD; and, ﬁnally, developing a pri-
oritised action plan to improve the needs detected and reduce
the repercussions of the disease.
Therefore, this multi-centre project, encompassing all
of Spain, is being proposed through a broad training
and information campaign, with continuing education and
enhancement of different research studies.
The intention of this article is to spread information on
the design of this project and some of its activities to offer it
as a platform that facilitates and stimulates research on and
knowledge of FD among Spanish nephrologists.
Methodology
General  design
The project will have an advisory committee headed by the
chairperson of the Spanish Society of Nephrology (SEN) who
will be in charge of driving, promoting and reviewing the
project; advising on the proposed aims; and involving all par-
ticipants effectively.
A  scientiﬁc committee will validate the general approach
of the project and the actions and studies to be carried out;
advise on the mode in which each action will be performed,
thereby ensuring maximum scientiﬁc rigour; select and pro-
duce required training materials (in person and online), review
the results obtained; and propose and reach an agreement on
future lines of research.
Regional committees will coordinate and execute the train-
ing activities required to improve knowledge of FD in their
region; advise on the mode in which each action will be per-
formed in the regions, thereby ensuring maximum scientiﬁc
rigour; review the results obtained in the area; and propose
and reach an agreement on future lines of research.
The following actions are proposed (Fig. 1):• Three multi-centre prevalence studies, which will be car-
ried out in accordance with the ethics requirements of the
declarations of Helsinki for research with human beings,;3 6(4):376–380
the good epidemiological practice guidelines of the Inter-
national Conference on Harmonisation and the existing
standards in Spain, and which will be approved by the rele-
vant ethics committees:
◦ In patients in dialysis, both haemodialysis and peritoneal
dialysis, with non-restrictive inclusion criteria.
◦ In renal transplant patients.
◦ In patients with stages 3–5 CKD predialysis; in this case
the study is proposed as a pilot.
• The protocols for the studies will be available on the website
enabled for the project. Access by and participation of any
SEN member will require prior approval of the project by the
scientiﬁc committee.
•  Study of the family tree among patients diagnosed with FD.
• The degree of knowledge of FD among nephrologists will
be quantiﬁed before and after the development of the plan
through a brief survey; in this way the training needs of all
of them with respect to the disease will be detected.
• University courses focused on FD and clinical genetics, and
regional on-site training sessions.
• An evidence-based review with analysis of all available
information on FD in the ﬁeld of Nephrology.
• A pharmacoeconomic study of the economic burden of FD
for society, the individual and the healthcare system.
• Finally, the results obtained from the projects and activities
performed will be collected and a white paper on FD will be
prepared that may serve as a basis for preparing recommen-
dations for early diagnosis of the disease in Nephrology.
Follow-up
In the course of the project the different committees will ana-
lyse the progress of the activities and studies, and propose
actions to improve those activities that require it. At least 3
annual meetings are planned for each committee.
Methodology  of  the  epidemiological  studies
In the prevalence studies and the analysis of the relatives of
patients diagnosed with FD, after obtaining informed consent
from all participants, a speciﬁc electronic case report form
(e-CRF) will be ﬁlled in for each study; all will be available
for restricted use by the investigators on the project website
(www.preﬁne.es). The e-CRF will include sociodemographic
variables, clinical disease events, any complications or impair-
ment of organs or systems that the patient may have and the
dates on which the patient started to have symptoms sugges-
tive of FD. As these are epidemiological projects of prevalence
in an at-risk population, the aim is to screen as many  patients
as possible. It is estimated that up to 10,000 dialysis patients
and 3000 transplant patients will be reached. The number of
CKD patients in the study has not been estimated as this is
a pilot study. Patient selection will be performed by means of
consecutive sampling of patients who visit Nephrology out-
patient clinics or are cared for at dialysis centres. Patients of
both sexes who meet the inclusion criteria for each study will
be accepted, without any age limit. The dialysis study pro-
tocol has been approved by the Hospital Clínic de Barcelona
Ethics Committee, and the transplant study protocol has been
approved by Hospital de Bellvitge in L’Hospitalet de Llobregat
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Fig. 1 – Actions.
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asque Country IEC.
All patients selected to participate will undergo a dried
lood spot analysis; male patients will undergo determina-
ion of their -galactosidase A enzyme activity, and when this
s below normal limits, they will undergo a genetic study of
he GLA gene; women will undergo a genetic study regard-
ess of their enzyme activity result. All patients will undergo
etermination of their lyso-Gb3 value.
A blood sample will be drawn from consenting patients and
tored in the RedinRen biobank. The sample will allow future
esearch to be conducted in these populations.
Patients with a positive result for FD will be evaluated
ccording to routine clinical practice at each site or will be
eferred to specialised sites with experience in management
f the disease, at the discretion of each investigator.
The SPSS statistical programme will be used for data
nalysis. Descriptive statistical analysis of the variables will
e performed. A statistical signiﬁcance level of 0.05 will be
sed. Preliminary statistical techniques will be used when
erforming hypothesis-verifying tests to ensure that statis-
ical assumptions are met. In the event that the establishedassumptions are not met, equivalence tests without these lim-
itations, such as non-parametric tests, will be used.
Discussion
The PrEFiNE project is the ﬁrst comprehensive plan to improve
knowledge of a rare disease in the ﬁeld of a medical speciality.
It may serve as a pilot project to improve knowledge of rare
diseases in target specialities.
Our hypothesis is that the range of activities aimed at all
nephrologists will allow knowledge and recognition of FD to be
improved and recommendations that facilitate management
of these patients to be established.
Therefore, it is hoped that this project will lead to a shift
in the current paradigm in diagnosis of the disease such that
time to diagnosis decreases and the long-term complications
that these patients have may be reduced.The results obtained will be very useful as they will allow
comparison between the results for the different stages of
CKD and subsequently comparison between these results and
results obtained in future studies.
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However, to achieve the proposed objectives, this project
requires the participation of the majority of Nephrology
Departments, which will be involved in both the training activ-
ities and the proposed lines of research. The data generated
during the project will follow the data use standards of the SEN
and will be transferred to the SEN once all proposed objectives
have been met.
Authorship standards will be established by the scientiﬁc
committee of the project.
We  would like this study to be considered to be a com-
mon  enterprise of the nephrologists of the SEN. It is also
our intention that this article which lays out the activities to
be performed stimulates collaboration to achieve the desired
objective.
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